Immunotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma After Platinum-Based Chemotherapy
PD-1 inhibitors should be offered to patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed following platinum-based therapy, with pembrolizumab, nivolumab, or toripalimab being reasonable options based on availability. 1
Evidence-Based Recommendation
The 2023 ASCO guideline provides a formal recommendation (Recommendation 4.2) that PD-1 inhibitors may be offered to this patient population, though the strength of recommendation is weak due to low-quality evidence 1. While no phase III trials demonstrate superiority over chemotherapy in the platinum-refractory setting, multiple phase II studies consistently show clinical benefit with substantially lower toxicity compared to standard chemotherapy.
Available PD-1 Inhibitors and Supporting Evidence
Pembrolizumab
The KEYNOTE-122 trial randomized 233 patients with platinum-refractory recurrent/metastatic NPC to pembrolizumab versus investigator's choice chemotherapy (capecitabine, gemcitabine, or docetaxel) 1. Key findings:
- Median OS was similar: 17.2 months for pembrolizumab versus 15.3 months for chemotherapy (HR 0.90; 95% CI 0.67-1.19; P=0.226)
- Dramatically lower toxicity: Treatment-related adverse events occurred in 61.2% versus 87.5%, with grade 3-5 toxicity at 10.3% versus 43.8% for pembrolizumab versus chemotherapy respectively
- OS benefit was independent of PD-L1 expression (CPS ≥1 showed similar outcomes)
Nivolumab
Two phase II studies support nivolumab use 1:
- NCI-4792: 44 platinum-pretreated patients received nivolumab 3 mg/kg every 2 weeks, achieving 21% objective response rate with 1-year OS of 59%
- CheckMate-358: 24 patients with nonkeratinizing disease showed 20.8% ORR, with responses independent of PD-L1 status
Toripalimab
The POLARIS-02 study enrolled 190 platinum-refractory patients 1:
- ORR: 20.5% (95% CI 15.0-27.0)
- Median OS: 17.4 months (95% CI 11.7-22.9)
- Responses were similar regardless of PD-L1 status (27.1% in PD-L1-positive versus 19.1% in PD-L1-negative; P=0.31)
- For heavily pretreated patients (≥2 prior lines), ORR was 23.9%
Clinical Decision Algorithm
Step 1: Confirm platinum-refractory status
- Disease progression during or within 6 months after platinum-based chemotherapy
Step 2: Select PD-1 inhibitor based on availability
- Pembrolizumab 200 mg IV every 3 weeks (up to 35 cycles)
- Nivolumab 240 mg IV every 2 weeks OR 3 mg/kg every 2 weeks
- Toripalimab 3 mg/kg every 2 weeks
Step 3: PD-L1 testing is NOT required
- All three agents show benefit independent of PD-L1 expression
- Do not delay treatment for biomarker results
Step 4: Continue until disease progression or unacceptable toxicity
- Monitor for immune-related adverse events
- Consider treatment beyond progression if clinical benefit continues
Key Advantages Over Chemotherapy
The primary rationale for PD-1 inhibitors in this setting centers on quality of life preservation rather than survival superiority 1:
- 3-4 fold reduction in grade 3-5 toxicity compared to chemotherapy
- Similar overall survival outcomes
- Lower treatment-related adverse event rates (61% versus 88%)
- Durable responses when they occur
Important Caveats
Evidence limitations: The recommendation carries a "weak" strength rating because no phase III trial has demonstrated statistically significant OS improvement over chemotherapy in the platinum-refractory setting 1. The KEYNOTE-122 trial showed a trend toward benefit (HR 0.90) but did not reach statistical significance.
Hyperprogressive disease risk: Some retrospective data suggest higher rates of hyperprogressive disease with immunotherapy monotherapy (39% versus 3.8% when combined with chemotherapy) 2, though this requires prospective validation.
EBV-negative disease: Most evidence derives from EBV-positive nonkeratinizing NPC, which represents the majority of cases globally. Efficacy in EBV-negative disease requires further evaluation 1.
Alternative Consideration: Combination Therapy
While not standard in the platinum-refractory setting, emerging evidence suggests PD-1 inhibitor plus chemotherapy may be superior to monotherapy for patients who can tolerate combination treatment 2, 3. However, this approach is primarily validated in the first-line setting with toripalimab, camrelizumab, or tislelizumab combined with gemcitabine-cisplatin 1.